NF-κB, demonstrated in hepatocellular carcinoma, increases the transcription of N-cadherin and decreases that of E-cadherin through the NF-κB signaling pathway when it is activated by receptor activator of nuclear factor kappa B ligand (RANKL) [84]. This evidence concerns the gene NFKB1 and hepatocellular carcinoma.